OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

a tasty rns out this morning ......

Oxford BioMedica said it had entered into an exclusive worldwide licensing agreement with Axovant Sciences to develop and commercialisea a gene therapy developed by the company for Parkinson's disease.

The agreement would see Axovant utilise Oxford BioMedica's LentiVector platform.

Under the terms of the agreement, Oxford BioMedica would receive a $30m upfront payment (£22m) including $5m as pre-payment for manufacturing activities related to OXB-102, now renamed, AXO-Lenti-PD.

Oxford BioMedica was also eligible to receive $55m on achievement of development milestones and $757.5m on achievement of regulatory and sales milestones, with 7% to 10% tiered royalties on net sales of AXO-Lenti-PD.

Game changer. Obviously no guarantees but $757m is potentially stratospheric....